| Ticker |
SOAGY
|
| CIK | N/A |
| SIC | N/A |
| Sector | N/A |
| Industry Category | N/A |
| Industry Group | N/A |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Sartorius AG Supervisory Board Extends Appointment of Board Member Rene FaberGOTTINGEN, GERMANY - March 26, 2026 (NEWMEDIAWIRE) - At today's meeting, the Supervisory Board of Sartorius AG resolved to extend the appointment of Dr. Ren Fber as a member of the Executive Board by a five-year period to December 31, 2031. Ren ... Sartorius Aktiengesellschaft AGM: 2025 Sales Hit €3.5B, New CEO, Dividend Plan and 2026 OutlookSartorius Aktiengesellschaft (ETR:SRT) used its 2026 Annual General Meeting to review financial performance for 2025, outline governance changes, and reiterate updated strategic and medium-term financial targets presented recently at its Capital Markets Day. AGM format, attendance, and governance u Assessing Sartorius (XTRA:SRT3) Valuation After The Eveo Cell Therapy Platform LaunchEveo Cell Therapy Platform launch and why it matters Sartorius (XTRA:SRT3) has drawn investor attention with the Eveo Cell Therapy Platform, a modular, closed system designed to ease manufacturing bottlenecks and reduce costs for autologous therapies such as CAR T treatments. See our latest analysis for Sartorius. The Eveo announcement comes after a recent investor day update on corporate strategy. Sartorius’s 30 day share price return of 12.13% and year to date share price return of 15.25%... Health Care Roundup: Market Talk0844 ET – Amplifon’s acquisition of Danish group GN Store Nord’s hearing-aid business will end the Italian company’s unique position as a retail-only group and hurt its stock, Jefferies analysts write. This change will outweigh positive synergies created by a deal that will add manufacturing to Amplifon’s hearing-aid business, they say. All-time low valuations across the hearing-aid sector are also not enough to support the stock, they add. Sartorius Aktiengesellschaft Capital Markets Day: Reaffirms Midterm Growth Targets, AI and Capacity PushSartorius Aktiengesellschaft (ETR:SRT) used its 2025 Capital Markets Day in Göttingen to outline strategic priorities, discuss midterm targets, and provide additional context on market conditions, technology investment and operational initiatives. The event brought together the executive board of CE |
